Literature DB >> 15833515

Increased intratumoral expression of prostate secretory protein of 94 amino acids predicts for worse disease recurrence and progression after radical prostatectomy in patients with prostate cancer.

Andrew R Girvan1, Peter Chang, Isaac van Huizen, Madeleine Moussa, Jim W Xuan, Larry Stitt, Joseph L Chin, Yasuto Yamasaki, Jonathan I Izawa.   

Abstract

OBJECTIVES: To examine the impact of prostate secretory protein of 94 amino acids (PSP94) expression within the primary tumor on disease recurrence and progression using radical prostatectomy specimens from patients with adenocarcinoma of the prostate.
METHODS: PSP94 immunohistochemistry was performed on 59 radical prostatectomy specimens. The degree of PSP94 expression was reported as either present (group 1) or absent (group 2). Clinical data, including survival outcome measures, were correlated with PSP94 expression.
RESULTS: The time to disease progression for group 1 was shorter compared with that for group 2 (P = 0.042). Disease-free survival was also less in group 1 than in group 2 (P = 0.033). Multivariate analyses demonstrated that PSP94 expression was an independent prognostic factor for a shorter interval to disease progression (P = 0.046) and disease-free survival (P = 0.049).
CONCLUSIONS: PSP94 expression in radical prostatectomy tumor specimens appears to be associated with worsened survival outcomes and may provide additional prognostic information.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15833515     DOI: 10.1016/j.urology.2004.10.058

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  11 in total

1.  Growth inhibition mediated by PSP94 or CRISP-3 is prostate cancer cell line specific.

Authors:  Bhakti R Pathak; Ananya A Breed; Vaishali H Nakhawa; Dhanashree D Jagtap; Smita D Mahale
Journal:  Asian J Androl       Date:  2010-08-02       Impact factor: 3.285

Review 2.  MSMB variation and prostate cancer risk: clues towards a possible fungal etiology.

Authors:  Siobhan Sutcliffe; Angelo M De Marzo; Karen S Sfanos; Martin Laurence
Journal:  Prostate       Date:  2014-01-24       Impact factor: 4.104

3.  Investigation of the relationship between prostate cancer and MSMB and NCOA4 genetic variants and protein expression.

Authors:  Liesel M FitzGerald; Xiaotun Zhang; Suzanne Kolb; Erika M Kwon; Ying Ching Liew; Antonio Hurtado-Coll; Beatrice S Knudsen; Elaine A Ostrander; Janet L Stanford
Journal:  Hum Mutat       Date:  2012-10-04       Impact factor: 4.878

4.  Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy.

Authors:  Anders S Bjartell; Hikmat Al-Ahmadie; Angel M Serio; James A Eastham; Scott E Eggener; Samson W Fine; Lene Udby; William L Gerald; Andrew J Vickers; Hans Lilja; Victor E Reuter; Peter T Scardino
Journal:  Clin Cancer Res       Date:  2007-07-15       Impact factor: 12.531

5.  Prospective validation of microseminoprotein-β added to the 4Kscore in predicting high-grade prostate cancer in an international multicentre cohort.

Authors:  Peter E Lonergan; Emily A Vertosick; Melissa Assel; Daniel D Sjoberg; Alexander Haese; Markus Graefen; Stephen A Boorjian; George G Klee; Matthew R Cooperberg; Kim Pettersson; Erica Routila; Andrew J Vickers; Hans Lilja
Journal:  BJU Int       Date:  2020-12-28       Impact factor: 5.969

6.  Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of PTEN deleted prostate cancers.

Authors:  Andreas M Luebke; Ali Attarchi-Tehrani; Jan Meiners; Claudia Hube-Magg; Dagmar S Lang; Martina Kluth; Maria Christina Tsourlakis; Sarah Minner; Ronald Simon; Guido Sauter; Franziska Büscheck; Frank Jacobsen; Andrea Hinsch; Stefan Steurer; Thorsten Schlomm; Hartwig Huland; Markus Graefen; Alexander Haese; Hans Heinzer; Till S Clauditz; Eike Burandt; Waldemar Wilczak; Doris Höflmayer
Journal:  Cancer Biol Med       Date:  2019-05       Impact factor: 4.248

Review 7.  The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review.

Authors:  Naveen Kachroo; Vincent J Gnanapragasam
Journal:  J Cancer Res Clin Oncol       Date:  2012-11-28       Impact factor: 4.553

Review 8.  Molecular markers for prostate cancer in formalin-fixed paraffin-embedded tissues.

Authors:  Tamara Sequeiros; Marta García; Melania Montes; Mireia Oliván; Marina Rigau; Eva Colás; Inés de Torres; Juan Morote; Jaume Reventós; Andreas Doll
Journal:  Biomed Res Int       Date:  2013-11-25       Impact factor: 3.411

9.  Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer.

Authors:  Liisa Sjöblom; Outi Saramäki; Matti Annala; Katri Leinonen; Janika Nättinen; Teemu Tolonen; Tiina Wahlfors; Matti Nykter; G Steven Bova; Johanna Schleutker; Teuvo L J Tammela; Hans Lilja; Tapio Visakorpi
Journal:  PLoS One       Date:  2016-03-03       Impact factor: 3.240

10.  Network-directed cis-mediator analysis of normal prostate tissue expression profiles reveals downstream regulatory associations of prostate cancer susceptibility loci.

Authors:  Nicholas B Larson; Shannon K McDonnell; Zach Fogarty; Melissa C Larson; John Cheville; Shaun Riska; Saurabh Baheti; Alexandra M Weber; Asha A Nair; Liang Wang; Daniel O'Brien; Jaime Davila; Daniel J Schaid; Stephen N Thibodeau
Journal:  Oncotarget       Date:  2017-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.